drugset / Trial / NCT02586402

Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on Dialysis

NCT02586402

Phase 2 Unknown 60 enrolled Jiangsu Hansoh Pharmaceutical Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of multiple intravenous doses of pegol-Sihematide in participants with chronic kidney disease (CKD) who are on dialysis.

Timeline

Start
2015-10
Primary completion
2016-08
Completion
2016-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Pegol-Sihematide Unknown Intravenous
Comparator epoetin alfa Protein / enzyme biologic